COVID 19 Vaccine for Adolescents. Concern about Myocarditis and PericarditisOpinion Published on 2021-09-012022-10-29 Journal: Pediatric Reports [Category] COVID-19, [키워드] acute SARS-CoV-2 infection administration concern COVID 19 COVID-19 COVID-19 mRNA vaccine criteria Critically ill discharged home disease European Evidence Health Inflammatory Kawasaki-like syndrome male Moderna mRNA-based vaccine multi-system inflammatory disease myocarditis occurred Patient Pericarditis Pfizer–BioNTech SARS-CoV-2 second dose syndrome the patient the vaccine Vaccine vaccine administration [DOI] 10.3390/pediatric13030061 PMC 바로가기 [Article Type] Opinion
Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2Review Published on 2021-08-312022-10-29 Journal: International Review of Cell and Molecular Biology [Category] COVID-19, [키워드] adverse effect anaphylactic approved Autoimmune challenge complex Coronaviruses COVID-19 COVID-19 mRNA vaccine COVID-19 pandemic Diseases Generation global public health knowledge less management mRNA mRNA vaccine mRNA vaccines mRNA-based vaccine previous study public health Research resource SARS-CoV-2 Side effects vaccination Vaccine Vaccine development Vaccine-induced immunity [DOI] 10.3390/life11090907 PMC 바로가기 [Article Type] Review
Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals2차 SARS-CoV-2 mRNA 백신 용량이 순진한 사람과 COVID-19에서 회복된 사람의 T 세포 면역에 미치는 차등 효과Article Published on 2021-08-242022-09-11 Journal: Cell Reports [Category] MERS, SARS, 진단, 치료기술, [키워드] accelerated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 BNT162b2 BNT162b2 vaccine cellular immunity Coronavirus-2 COVID-19 demonstrated dose Effect effective Efficacy first dose humoral Immunity immunization increase individual individuals infected individual infected with SARS-CoV-2 investigated mRNA mRNA vaccine mRNA-based vaccine mRNA-based vaccines naïve individuals of BNT162b2 regimen respiratory SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike-specific second dose Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 T cell T-cell immunity vaccination vaccination schedule vaccine dose while [DOI] 10.1016/j.celrep.2021.109570 PMC 바로가기 [Article Type] Article
Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populationsSARS-COV-2의 BNT162B2 mRNA 백신 접종에 대한 안전성 및 유머 반응, 이전에 감염되고 순진한 집단Comparative Study Published on 2021-08-162022-09-01 Journal: Scientific Reports [Category] MERS, SARS, 진단, [키워드] BNT162b2 BNT162b2 mRNA COVID-19 vaccine BNT162b2 mRNA vaccination Cohort correlation COVID-19 COVID-19 vaccine demonstrated dose Efficacy Humoral response immune response individual individuals induce Infection Injections mRNA mRNA-based vaccine mRNA-based vaccines naïve of BNT162b2 Population populations regimen Reinfection required response risk Safe Safety SARS-CoV-2 serological Serological tests Seropositivity severe symptom single dose single vaccine Symptom the median vaccination vaccine dose vaccine injection Vaccines viral infection [DOI] 10.1038/s41598-021-96129-6 PMC 바로가기 [Article Type] Comparative Study
Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare WorkersArticle Published on 2021-08-052022-10-28 Journal: Biology [Category] COVID-19, [키워드] adverse effects age approved AstraZeneca BTN162 vaccine carried ChAdOx1 COVID-19 vaccine chill conducted coronavirus COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines cross-sectional Cross-sectional studies demographic data drug-related side effects and adverse reactions Effect ENhance evaluate females Gender Germany Health personnel healthcare healthcare worker increased risk injection site injection site pain joint knowledge Local majority malaise methodology Moderna mRNA-1273 vaccine mRNA-based mRNA-based vaccine mRNA-based vaccines overcome Pain parameters participant Pfizer-BioNTech Prevalence questionnaire reliability reported resolved risk factor safety point side Side effect simple systemic side effect systemic side effects tested vaccination Vaccine Vaccine hesitancy Vaccines viral vector-based worker [DOI] 10.3390/biology10080752 PMC 바로가기 [Article Type] Article
Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 VaccinesReview Published on 2021-08-032022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] Adenovirus vector-based vaccine Anaphylactic reaction antibody Antigen presentation cause CD1 cellular composed conformational change coronavirus 2 COVID-19 DNA sequences effective vaccine epitope events glycol immune immune system induce MHC class I mRNA mRNA vaccine mRNA-based vaccine pandemic Patient platelet factor 4 Polyethylene glycol presentation produced proportions Protein reached respiratory S1 protein SARS-CoV-2 secretion Side effects spike Spike protein T-lymphocytes the SARS-CoV-2 thrombosis triggered Vaccine Viral protein Viral vector vaccine Viral vector vaccines virus-neutralizing antibody [DOI] 10.3390/vaccines9080848 PMC 바로가기 [Article Type] Review
Covid-19 pandemic: Perspectives on management코로나19 팬데믹: 경영에 대한 관점Review Published on 2021-08-012022-09-11 Journal: Journal of reproductive immunology [Category] SARS, 임상, 치료제, [키워드] ACE ACE inhibitors angiotensin Angiotensin receptor blockers assisted ventilation benefit Care clinical trials country COVAX COVID-19 COVID-19 vaccines decrease develop Dexamethasone dissemination distribution drug effective effective drug effective drugs effective therapy Efficacy Evidence evidence of form hypoxia ICU care identify in vitro activity Infection low dose dexamethasone management medical treatment Mild mRNA-based vaccine pandemic Patient Pneumonia preliminary evidence preventing infection progression provided randomized trial randomized trials receptor refrigeration Regulatory Remdesivir required retroviral SARS-CoV-2 severe disease shown supportive care the WHO Treatment vaccination Vaccine Vaccines virus [DOI] 10.1016/j.jri.2021.103344 PMC 바로가기 [Article Type] Review
Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients간 이식 환자 중 SARS-CoV-2 백신 접종에 대한 낮은 면역원성Article Published on 2021-08-012022-09-11 Journal: Journal of hepatology [Category] MERS, SARS, 진단, 치료법, [키워드] age All participant All participants antibody Antibody Response Antibody titer approved average BNT162b2 center Clinical data Control controls COVID-19 COVID-19 infection dose Efficacy elicited enrolled Factor female filtration rate glomerular filtration rate healthy healthy controls healthy volunteer healthy volunteers High dose IgG IgG antibodies Immunity immunogenicity Immunological response immunosuppressive medications include less levels of antibody liver liver transplant Liver transplantation medical records mRNA vaccine mRNA-based vaccine mycophenolate mycophenolate mofetil N-protein nucleocapsid Older age Patient Pfizer Pfizer-BioNTech Pfizer-BioNTech BNT162b2 positive positive serology Prevent receiving recipient recipients regimen renal function reported risk S-protein SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 IgG antibodies SARS-CoV-2 IgG antibody SARS-CoV-2 vaccination SARS-CoV-2 vaccine Serious Adverse Event Serious Adverse Events serological serology Side effect significantly lower Special Population spike-protein steroid Steroids tested the patient Treatment trials vaccination Vaccine vaccine immunogenicity virus was collected [DOI] 10.1016/j.jhep.2021.04.020 PMC 바로가기 [Article Type] Article
Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-VaccinationArticle Published on 2021-07-312022-10-31 Journal: Cells [Category] COVID-19, SARS, [키워드] anti-SARS-CoV-2 IgG antibody Antibody titer blood sample cellular response Cohort Comirnaty Concentration COVID-19 difference eight subject enzyme-linked immunosorbent assays evaluate first dose greater healthy subject highest humoral humoral immune response Humoral response IgG IgG antibody individual individuals less levels of antibody marker mRNA vaccine mRNA-based vaccine Participants Patient Protective Regular second dose serological serological measurement seronegative seropositive significantly Spike protein symptomatic and asymptomatic T cell the S1 subunit vaccination was measured [DOI] 10.3390/cells10081952 PMC 바로가기 [Article Type] Article
Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients신장 이식 환자에서 SARS-CoV-2 BNT162b2(토지나메란) 프라임-부스트 백신 접종 후 체액 및 세포 면역 손상Article Published on 2021-07-152022-09-12 Journal: The Journal of Clinical Investigation [Category] SARS, 진단, [키워드] accompanied Adaptive immunity Affect age analyzed antibody approach BNT162b2 booster caused CD4+ CD8+ T cell cellular immunity cellular response change combating Control COVID-19 cytokine production dialysis dose Frequency global pandemic healthy healthy control Hemodialysis humoral IgA IgG immune immunization immunology immunosuppressed patients Immunosuppressive medication Impaired impairment individual kidney transplant recipient less majority memory mounted mRNA-based vaccine novel organ transplantation Patient patients powerful tool promotion reduced rejection renal response responses risk SARS-CoV-2 SARS-CoV-2 BNT162b2 second vaccination Seroconversion severe COVID-19 significantly Still T cells T helper cell transplantation undetectable vaccination Vaccine-induced immunity vaccinee [DOI] 10.1172/JCI150175 PMC 바로가기 [Article Type] Article